Business briefs: Gilead, Bristol-Myers Squibb and GlaxoSmithKline

Share this article:

A two-year study of HIV drug regimens shows Gilead's Striblid quad pill edges out three-part Atripla in virus suppression, with 84% of quad pill patients reaching undetectable levels compared with viral suppression of 82% of patients on Atripla, which is co-marketed by Gilead and Bristol-Myers Squibb, reports Medpage Today. The findings showed similar efficacy among patients younger than 40 and older than 40, and across sexes and ethnic backgrounds.

GlaxoSmithKline submitted an sNDA to the FDA so its BRAF inhibitor dabrafenib and MEK inhibitor trametinib can be paired up to treat metastatic melanoma. GSK submitted sNDAs for each of the drugs so they can be used in a two-for-one setting. Phase II studies comparing dabrafenib monotherapy vs. combination treatment are the basis of the proposal. The drug maker's oncology efforts also include its recent deal with the British biotech Immunocore. The deal focuses on developing ImmTACs to treat cancers and viral diseases. The deal gives $181 million to Immunocore now, with the promise of up to $255 million in additional milestone payments.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.